Abstract
The conventional way of characterizing a disease consists of correlating clinical symptoms with pathological findings. Although this approach for many years has assisted clinicians in establishing syndromic patterns for pathophenotypes, it has major limitations as it does not consider preclinical disease states and is unable to individualize medicine. Moreover, the complexity of disease biology is the major challenge in the development of effective and safe medicines. Therefore, the process of drug development must consider biological responses in both pathological and physiological conditions. Consequently, a quantitative and holistic systems biology approach could aid in understanding complex biological systems by providing an exceptional platform to integrate diverse data types with molecular as well as pathway information, leading to development of predictive models for complex diseases. Furthermore, an increase in knowledgebase of proteins, genes, metabolites from high-throughput experimental data accelerates hypothesis generation and testing in disease models. The systems biology approach also assists in predicting drug effects, repurposing of existing drugs, identifying new targets, facilitating development of personalized medicine and improving decision making and success rate of new drugs in clinical trials.
Keywords: Network models, Dynamical models, Biomarkers, Drug repurposing, Drug combinations, CVD.
Current Topics in Medicinal Chemistry
Title:Systems Biology: A Powerful Tool for Drug Development
Volume: 18 Issue: 20
Author(s): Sneha Rai, Utkarsh Raj and Pritish Kumar Varadwaj*
Affiliation:
- Department of Bioinformatics & Applied Sciences, Indian Institute of Information Technology, Allahabad, Uttar Pradesh,India
Keywords: Network models, Dynamical models, Biomarkers, Drug repurposing, Drug combinations, CVD.
Abstract: The conventional way of characterizing a disease consists of correlating clinical symptoms with pathological findings. Although this approach for many years has assisted clinicians in establishing syndromic patterns for pathophenotypes, it has major limitations as it does not consider preclinical disease states and is unable to individualize medicine. Moreover, the complexity of disease biology is the major challenge in the development of effective and safe medicines. Therefore, the process of drug development must consider biological responses in both pathological and physiological conditions. Consequently, a quantitative and holistic systems biology approach could aid in understanding complex biological systems by providing an exceptional platform to integrate diverse data types with molecular as well as pathway information, leading to development of predictive models for complex diseases. Furthermore, an increase in knowledgebase of proteins, genes, metabolites from high-throughput experimental data accelerates hypothesis generation and testing in disease models. The systems biology approach also assists in predicting drug effects, repurposing of existing drugs, identifying new targets, facilitating development of personalized medicine and improving decision making and success rate of new drugs in clinical trials.
Export Options
About this article
Cite this article as:
Rai Sneha , Raj Utkarsh and Varadwaj Kumar Pritish *, Systems Biology: A Powerful Tool for Drug Development, Current Topics in Medicinal Chemistry 2018; 18 (20) . https://dx.doi.org/10.2174/1568026618666181025113226
DOI https://dx.doi.org/10.2174/1568026618666181025113226 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design Improving the Classification of Nuclear Receptors with Feature Selection
Protein & Peptide Letters Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases
Current Cancer Drug Targets Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types
Anti-Cancer Agents in Medicinal Chemistry A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms
Mini-Reviews in Medicinal Chemistry Comparative Proteomics Analysis of SKBR3 and MCF7 Breast Cancer Cell Lines Using Two Dimensional Electrophoresis: Ready to Build Postgenomics Capacity for OMICS R&D in Developing Countries?
Current Pharmacogenomics and Personalized Medicine Integrative System Biology Strategies for Disease Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Combination Therapy for the Treatment of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Current Drug Metabolism Targeting the EGF/HER Ligand-Receptor System in Cancer
Current Pharmaceutical Design Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging
Current Pharmaceutical Design N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Anti-Cancer Agents in Medicinal Chemistry The Design of Vectors for RNAi Delivery System
Current Pharmaceutical Design Mouse Models of Autoimmune Diseases
Current Drug Discovery Technologies Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research